KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Share-based Compensation: 2020-2025

Historic Share-based Compensation for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $13.9 million.

  • AbCellera Biologics' Share-based Compensation fell 19.05% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year decrease of 15.54%. This contributed to the annual value of $67.6 million for FY2024, which is 5.29% up from last year.
  • AbCellera Biologics' Share-based Compensation amounted to $13.9 million in Q3 2025, which was down 2.20% from $14.2 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Share-based Compensation high stood at $17.8 million for Q2 2024, and its period low was $5.4 million during Q1 2021.
  • Over the past 3 years, AbCellera Biologics' median Share-based Compensation value was $15.9 million (recorded in 2023), while the average stood at $15.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 1,298.18% in 2021, then decreased by 20.10% in 2025.
  • AbCellera Biologics' Share-based Compensation (Quarterly) stood at $9.0 million in 2021, then soared by 47.41% to $13.3 million in 2022, then climbed by 23.46% to $16.4 million in 2023, then declined by 7.43% to $15.2 million in 2024, then declined by 19.05% to $13.9 million in 2025.
  • Its last three reported values are $13.9 million in Q3 2025, $14.2 million for Q2 2025, and $14.8 million during Q1 2025.